医疗保健医药品製造委託(CMO)的全球市场预测(2022年～2027年)

全球医疗保健医药品製造委託(CMO)的市场规模在2020年估算为1,633亿9,000万美金，以年复合成长率8.42％的速度成长，到2027年达到2,876亿8,400万美元。

本报告提供全球医疗保健医药品製造委託(CMO)市场相关调查，提供市场规模和预测，COVID-19影响，市场促进因素及课题，市场趋势，各市场区隔的市场分析，竞争情形，主要企业的简介等系统性资讯。

目录

第1章 简介

• 市场概要
• COVID-19影响
• 市场定义
• 市场区隔

第2章 调查手法

• 调查资料
• 前提条件

第3章 摘要整理

• 调查的重点

第4章 市场动态

• 推动市场要素
• 阻碍市场要素
• 波特的五力分析
  • 供给企业谈判力
  • 买方议价能力
  • 新加入厂商者的威胁
  • 替代品的威胁
  • 竞争企业间的敌对关係
• 产业的价值链分析

第5章 医疗保健医药品製造委託(CMO)市场分析:各类服务

• 简介
• 医药品CMO
  • 医药品有效成分(API)的製造
  • 最后用量製剂(FDF)的製造
  • 包装
• 医疗设备CMO
  • 设计委託
  • 设备製造
  • 最终产品组装

第6章 医疗保健医药品製造委託(CMO)市场分析:各类型

• 简介
• 无菌
• 非杀菌

第7章 医疗保健医药品製造委託(CMO)市场分析:各地区

• 简介
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 南美
  • 巴西
  • 阿根廷
  • 其他
• 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 其他
• 中东·非洲
  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 以色列
  • 其他
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 台湾
  • 泰国
  • 印尼
  • 其他

第8章 竞争环境与分析

• 主要企业策略分析
• 新兴企业与市场的有利性
• 合併，收购，契约，合作
• 供应商的竞争矩阵

第9章 企业简介

• Jubilant Pharma Limited
• Pfizer Inc.
• Lonza Group
• AGC Biologics
• Recipharm AB
• Catalent, Inc.
• The Aenova Group
• Baxter
• Boehringer Ingelheim International GmbH
• DPx Holdings

The healthcare contract manufacturing outsourcing market is expected to grow at a CAGR of 8.42%, reaching a market size of US$287.684 billion in 2027 from US$163.39 billion in 2020.

Like every other business, Healthcare Sector also leverages the outsourcing process in the manufacture of drugs or medical devices. Contract manufacturing is a method for getting drugs and devices manufactured by an outsourcing firm dealing in that business. The increasing number of patients puts pressure on hospitals to maintain appropriate facilities to meet expectations in terms of infrastructure, workforce, medicine, and equipment. Outsourcing of some of the processes, like drug or medical device manufacturers, is being demanded by the healthcare sector to be able to focus on core competencies while minimizing the cost of operations.

Experience and expertise in the Healthcare outsourcing manufacturing market are driving the demand for such a market. On top of that, healthcare providers can avoid unnecessary capital investments, which might strain their resources. New players, willing to enter the healthcare market, can outsource the manufacture of drugs and devices to sustain their existence while providing quality services. The cost factor is the major reason for the booming Healthcare CMO market. Bypassing the process of hiring experts and saving time is an added advantage for the customers of this market.

The increased productivity while reducing the probability of errors is contributing to the market growth in the forecast period.

Mistakes in the healthcare sector can be fatal for the patient and destroy the hard-earned earnings of the service provider. Healthcare CMO companies tend to remain up-to-date with the latest changes in the industry and can provide optimal solutions to their customers. This adds to the growth of the companies in this sector. Drug R&D is an expensive endeavor, which is one of the primary reasons why the Healthcare CMO Industry is thriving. Besides, governmental pressure to remain competitive and efficient while ensuring the safety of patients is shaping the way the healthcare sector is transforming. Patent expiration is also a major reason why companies are resorting to healthcare CMO. Due to economies of scale, CMO companies are able to minimize the cost of drug production and can maintain their profits while letting the healthcare service provider maintain their incremental profit.

The Asia Pacific region is expected to show higher growth prospects in the forecast period due to high dependence on healthcare CMO firms from developed countries.

To meet the rising demand for medical equipment for surgeries and other medical aids, countries, such as India, are outsourcing the manufacture of these devices while maintaining their quality standards. Developed countries, such as America, have significantly invested in updating and upgrading their facilities and enhancing production more efficiently. America shares a substantial portion of the pie of this market due to the presence of a large number of pharmaceutical companies. The European region also holds a major portion of the market due to high governmental support and the booming biopharmaceutical sector.

Key Developments:

• May 2022: A $149.6 million cooperative agreement has been reached between the US government and Jubilant HollisterStier LLC (JHS), a pharmaceutical contract manufacturer with offices in the US and a subsidiary of Jubilant Pharma Limited, to increase critical vaccine production capacity. The contract was negotiated with Army Contracting Command on behalf of the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) and in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense. The transaction, which was paid for by the American Rescue Plan, will allow the business to increase its injectable filler production capacity.
• June 2022: In order to support the ongoing fight against COVID-19, Pfizer Inc. and BioNTech SE recently announced a new vaccine supply deal with the US government. According to the deal, 105 million doses (30 g, 10 g, and 3 g) will be given to the U.S. government. In adults, Omicron-adapted COVID-19 vaccinations may be used, but only with the U.S. Food and Drug Administration's permission (FDA). The doses are anticipated to start being given as early as the last quarter of this year, in late summer 2022. Upon receiving the first 105 million doses, the US government will pay the businesses $3.2 billion. The overall amount of possible doses under this arrangement is 300 million, with the U.S. government having the option to buy up to 195 million extra doses.

Product Offerings:

• Lonza cGMP Manufacturing: Autologous and allogeneic cell treatments as well as viral vector gene therapy are all covered by cGMP manufacturing capabilities, which span three continents. It can aid in the commercialization of novel treatments at various phases of their clinical development. The NPI program uses experience and decades of expertise in building cGMP manufacturing standards, combining corporate and local quality standards, tailored for cell and gene therapies, to reduce the risk associated with clients' path to commercialization.
• AGC Biologics formulation development: AGC Biologics creates formulations for lyophilized drug products, liquid drug substances, and drug products (together with optimised lyophilization cycles). Utilizing Design of Experiment (DOE) principles, they create extensive, quick excipient screening experiments to find excipients and circumstances that promote the greatest possible product stability. To produce an ideal formulation, they carefully examine various excipients and circumstances in combination using real-time and expedited stability studies. Formulations are created at dosage concentrations ranging from micrograms to >175 mg/mL.

Segmentation:

• By Services

Pharmaceutical CMO

• Active Pharmaceutical Ingredients (API) Manufacturing
• Final Dose Formulation (FDF) Manufacturing
• Injectable Dose Formulations
• Solid Dose Formulations
• Semi-solid Dose Formulations
• Liquid Dose Formulations
• Packaging

Medical Device CMO

• Design Outsourcing
• Device Manufacturing
• Final Goods Assembly
• By Type

Sterile

Non-Sterile

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• UK
• Germany
• France
• Italy
• Others

Middle East and Africa

• Saudi Arabia
• UAE
• Israel
• Others

Asia Pacific

• Japan
• China
• India
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Overview
• 1.2. COVID-19 Scenario
• 1.3. Market Definition
• 1.4. Market Segmentation

2. Research Methodology

• 2.1. Research Data
• 2.2. Assumptions

3. Executive Summary

• 3.1. Research Highlights

4. Market Dynamics

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. Healthcare Contract Manufacturing Outsourcing Market Analysis, by Services

• 5.1. Introduction
• 5.2. Pharmaceutical CMO
  • 5.2.1. Active Pharmaceutical Ingredients (API) Manufacturing
  • 5.2.2. Final Dose Formulation (FDF) Manufacturing
    • 5.2.2.1. Injectable Dose Formulations
    • 5.2.2.2. Solid Dose Formulations
    • 5.2.2.3. Semi-solid Dose Formulations
    • 5.2.2.4. Liquid Dose Formulations
  • 5.2.3. Packaging
• 5.3. Medical Device CMO
  • 5.3.1. Design Outsourcing
  • 5.3.2. Device Manufacturing
  • 5.3.3. Final Goods Assembly

6. Healthcare Contract Manufacturing Outsourcing Market Analysis, by Type

• 6.1. Introduction
• 6.2. Sterile
• 6.3. Non-sterile

7. Healthcare Contract Manufacturing Outsourcing Market Analysis, by Geography

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. United States
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. UK
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Others
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. United Arab Emirates
  • 7.5.3. Israel
  • 7.5.4. Others
• 7.6. Asia Pacific
  • 7.6.1. Japan
  • 7.6.2. China
  • 7.6.3. India
  • 7.6.4. South Korea
  • 7.6.5. Taiwan
  • 7.6.6. Thailand
  • 7.6.7. Indonesia
  • 7.6.8. Others

8. Competitive Environment and Analysis

• 8.1. Major Players and Strategy Analysis
• 8.2. Emerging Players and Market Lucrativeness
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Vendor Competitiveness Matrix

9. Company Profiles

• 9.1. Jubilant Pharma Limited
• 9.2. Pfizer Inc.
• 9.3. Lonza Group
• 9.4. AGC Biologics
• 9.5. Recipharm AB
• 9.6. Catalent, Inc.
• 9.7. The Aenova Group
• 9.8. Baxter
• 9.9. Boehringer Ingelheim International GmbH
• 9.10. DPx Holdings